Advent International, a private equity firm based in Boston, Massachusetts, is considering a buyout deal for drugmaker Swedish Orphan Biovitrum.
Advent has approached other buyout firms including Permira in an attempt to lead a consortium for the acquisition of the Swedish biotech firm.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
It is also weighing to bring in sovereign wealth funds for the bid. The talks are at an early stage, and it is not yet clear that they will ultimately lead to a deal, according to the people.
Source: Seeking Alpha
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...